Royal Bank Of Canada Issues Positive Forecast for Bausch + Lomb (NYSE:BLCO) Stock Price

Bausch + Lomb (NYSE:BLCO) had its price objective increased by analysts at Royal Bank Of Canada from $21.00 to $23.00 in a report issued on Thursday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Royal Bank Of Canada‘s price target points to a potential upside of 12.04% from the stock’s previous close.

A number of other research analysts have also weighed in on the stock. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $20.00 price objective on shares of Bausch + Lomb in a research note on Thursday. UBS Group started coverage on Bausch + Lomb in a research report on Thursday, July 30th. They set a “buy” rating and a $21.00 target price on the stock. Leerink Partners assumed coverage on Bausch + Lomb in a report on Wednesday, September 9th. They issued an “outperform” rating and a $24.00 price target for the company. Citigroup reiterated a “buy” rating on shares of Bausch + Lomb in a research report on Thursday. Finally, Wells Fargo & Company increased their price target on shares of Bausch + Lomb from $18.00 to $19.00 and gave the stock an “equal weight” rating in a report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $20.00.

Bausch + Lomb Stock Up 0.6%

NYSE BLCO traded up $0.13 during trading hours on Thursday, hitting $20.53. The company’s stock had a trading volume of 2,654,697 shares, compared to its average volume of 462,677. The company has a market capitalization of $7.34 billion, a PE ratio of -42.60, a price-to-earnings-growth ratio of 0.55 and a beta of 0.56. The company has a current ratio of 1.55, a quick ratio of 1.02 and a debt-to-equity ratio of 0.79. Bausch + Lomb has a 52 week low of $14.44 and a 52 week high of $21.36. The company’s 50-day simple moving average is $17.24 and its two-hundred day simple moving average is $16.66.

Bausch + Lomb (NYSE:BLCO) last posted its quarterly earnings data on Wednesday, October 28th. The company reported $0.34 EPS for the quarter, beating the consensus estimate of $0.21 by $0.13. The firm had revenue of $1.38 billion during the quarter, compared to analyst estimates of $1.37 billion. Bausch + Lomb had a negative net margin of 3.21% and a positive return on equity of 4.14%. The company’s revenue for the quarter was up 7.3% on a year-over-year basis. During the same quarter last year, the business posted $0.18 EPS. Research analysts anticipate that Bausch + Lomb will post 0.81 EPS for the current fiscal year.

Insider Buying and Selling at Bausch + Lomb

In other news, CAO Frederick Munsch sold 52,900 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $16.78, for a total value of $887,662.00. Following the sale, the chief accounting officer directly owned 45,831 shares of the company’s stock, valued at $769,044.18. This represents a 53.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Eschenbach Andrew C. Von sold 6,059 shares of Bausch + Lomb stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $16.58, for a total value of $100,458.22. Following the completion of the transaction, the director directly owned 63,733 shares of the company’s stock, valued at approximately $1,056,693.14. This represents a 8.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 71,459 shares of company stock worth $1,194,370. 1.45% of the stock is owned by insiders.

Institutional Investors Weigh In On Bausch + Lomb

A number of hedge funds have recently modified their holdings of the business. Whitebox Advisors LLC boosted its stake in Bausch + Lomb by 15.8% in the 1st quarter. Whitebox Advisors LLC now owns 1,101,854 shares of the company’s stock worth $17,519,000 after purchasing an additional 150,641 shares during the period. Beach Point Capital Management LP purchased a new stake in Bausch + Lomb in the 3rd quarter worth $5,882,000. Sei Investments Co. boosted its holdings in shares of Bausch + Lomb by 100.0% during the 1st quarter. Sei Investments Co. now owns 139,266 shares of the company’s stock valued at $2,214,000 after purchasing an additional 69,633 shares during the last quarter. Engineers Gate Manager LP bought a new stake in shares of Bausch + Lomb in the second quarter worth about $1,479,000. Finally, Dimensional Fund Advisors LP lifted its position in shares of Bausch + Lomb by 13.2% in the first quarter. Dimensional Fund Advisors LP now owns 85,779 shares of the company’s stock worth $1,362,000 after buying an additional 9,971 shares in the last quarter. Institutional investors own 11.07% of the company’s stock.

Key Stories Impacting Bausch + Lomb

Here are the key news stories impacting Bausch + Lomb this week:

• Positive Sentiment: Q3 earnings beat expectations: Adjusted EPS was $0.34, well above the $0.21–$0.22 analyst consensus and up from $0.18 a year earlier. Revenue reached approximately $1.38 billion, slightly ahead of estimates and 7.3% higher year over year. Bausch + Lomb Q3 earnings beat estimates
• Positive Sentiment: Full-year guidance was raised: Management now expects 2026 revenue of $5.450 billion to $5.550 billion and adjusted EBITDA of $1.090 billion to $1.140 billion, citing continued momentum from its Vision ’27 strategy and growth in eye-care products. Bausch + Lomb raises 2026 guidance
• Positive Sentiment: Profitability improved: The company swung to a quarterly profit on an adjusted basis, with earnings growth outpacing revenue growth. This stronger operating performance is the primary reason investors are reacting favorably to the latest updates. Bausch + Lomb swings to profit and raises guidance

Bausch + Lomb Company Profile

Bausch + Lomb Corporation (NYSE: BLCO) is a global eye-health company that develops, manufactures and markets products for vision care, ophthalmic pharmaceuticals and eye surgery. The company serves consumers, eye-care professionals, hospitals and surgical centers through a portfolio spanning contact lenses, contact-lens care products, prescription medicines, over-the-counter eye-care products and surgical equipment.

Its vision-care portfolio includes the Biotrue and INFUSE contact-lens brands, as well as solutions and other products used to clean and maintain contact lenses.